Lobbyists Worry Private Plans Might Follow CMS' Lead On 340B Pay Cuts

By Michelle M. Stein / November 14, 2017 at 6:22 PM
Medicare Advantage plans and commercial payers might follow CMS' lead in cutting pay to hospitals for drugs bought through the 340B drug discount program, lobbyists say. A spokesperson for 340B Health says there could be broader ramifications from CMS' policy than the agency considered, and those ramifications could undermine the drug discount program. CMS on Wednesday (Nov. 1) announced plans to cut hospital reimbursement for Part B drugs purchased through 340B by nearly 30 percent, from 106 percent of average...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.